Cargando…

Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways

BACKGROUND: High levels of thymidine kinase 1 (TK1) and thymidine phosphorylase (TYMP) are key molecular targets by thymidine therapeutics in cancer treatment. The dual roles of TYMP as a tumor growth factor and a key activation enzyme of anticancer metabolites resulted in a mixed outcome in cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Qiong, Liu, Haijuan, Zhou, Honghao, Zhang, Dejun, Zhang, Zhiwei, Zhou, Qibing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374574/
https://www.ncbi.nlm.nih.gov/pubmed/25881156
http://dx.doi.org/10.1186/s12885-015-1149-5
_version_ 1782363510480568320
author Wei, Qiong
Liu, Haijuan
Zhou, Honghao
Zhang, Dejun
Zhang, Zhiwei
Zhou, Qibing
author_facet Wei, Qiong
Liu, Haijuan
Zhou, Honghao
Zhang, Dejun
Zhang, Zhiwei
Zhou, Qibing
author_sort Wei, Qiong
collection PubMed
description BACKGROUND: High levels of thymidine kinase 1 (TK1) and thymidine phosphorylase (TYMP) are key molecular targets by thymidine therapeutics in cancer treatment. The dual roles of TYMP as a tumor growth factor and a key activation enzyme of anticancer metabolites resulted in a mixed outcome in cancer patients. In this study, we investigated the roles of TK1 and TYMP on a thymidine quinoxaline conjugate to evaluate an alternative to circumvent the contradictive role of TYMP. METHODS: TK1 and TYMP levels in multiple liver cell lines were assessed along with the cytotoxicity of the thymidine conjugate. Cellular accumulation of the thymidine conjugate was determined with organelle-specific dyes. The impacts of TK1 and TYMP were evaluated with siRNA/shRNA suppression and pseudoviral overexpression. Immunohistochemical analysis was performed on both normal and tumor tissues. In vivo study was carried out with a subcutaneous liver tumor model. RESULTS: We found that the thymidine conjugate had varied activities in liver cancer cells with different levels of TK1 and TYMP. The conjugate mainly accumulated at endothelial reticulum and was consistent with cytosolic pathways. TK1 was responsible for the cytotoxicity yet high levels of TYMP counteracted such activities. Levels of TYMP and TK1 in the liver tumor tissues were significantly higher than those of normal liver tissues. Induced TK1 overexpression decreased the selectivity of dT-QX due to the concurring cytotoxicity in normal cells. In contrast, shRNA suppression of TYMP significantly enhanced the selective of the conjugate in vitro and reduced the tumor growth in vivo. CONCLUSIONS: TK1 was responsible for anticancer activity of dT-QX while levels of TYMP counteracted such an activity. The counteraction by TYMP could be overcome with RNA silencing to significantly enhance the dT-QX selectivity in cancer cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1149-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4374574
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43745742015-03-27 Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways Wei, Qiong Liu, Haijuan Zhou, Honghao Zhang, Dejun Zhang, Zhiwei Zhou, Qibing BMC Cancer Research Article BACKGROUND: High levels of thymidine kinase 1 (TK1) and thymidine phosphorylase (TYMP) are key molecular targets by thymidine therapeutics in cancer treatment. The dual roles of TYMP as a tumor growth factor and a key activation enzyme of anticancer metabolites resulted in a mixed outcome in cancer patients. In this study, we investigated the roles of TK1 and TYMP on a thymidine quinoxaline conjugate to evaluate an alternative to circumvent the contradictive role of TYMP. METHODS: TK1 and TYMP levels in multiple liver cell lines were assessed along with the cytotoxicity of the thymidine conjugate. Cellular accumulation of the thymidine conjugate was determined with organelle-specific dyes. The impacts of TK1 and TYMP were evaluated with siRNA/shRNA suppression and pseudoviral overexpression. Immunohistochemical analysis was performed on both normal and tumor tissues. In vivo study was carried out with a subcutaneous liver tumor model. RESULTS: We found that the thymidine conjugate had varied activities in liver cancer cells with different levels of TK1 and TYMP. The conjugate mainly accumulated at endothelial reticulum and was consistent with cytosolic pathways. TK1 was responsible for the cytotoxicity yet high levels of TYMP counteracted such activities. Levels of TYMP and TK1 in the liver tumor tissues were significantly higher than those of normal liver tissues. Induced TK1 overexpression decreased the selectivity of dT-QX due to the concurring cytotoxicity in normal cells. In contrast, shRNA suppression of TYMP significantly enhanced the selective of the conjugate in vitro and reduced the tumor growth in vivo. CONCLUSIONS: TK1 was responsible for anticancer activity of dT-QX while levels of TYMP counteracted such an activity. The counteraction by TYMP could be overcome with RNA silencing to significantly enhance the dT-QX selectivity in cancer cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1149-5) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-21 /pmc/articles/PMC4374574/ /pubmed/25881156 http://dx.doi.org/10.1186/s12885-015-1149-5 Text en © Wei et al.; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wei, Qiong
Liu, Haijuan
Zhou, Honghao
Zhang, Dejun
Zhang, Zhiwei
Zhou, Qibing
Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways
title Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways
title_full Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways
title_fullStr Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways
title_full_unstemmed Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways
title_short Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways
title_sort anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374574/
https://www.ncbi.nlm.nih.gov/pubmed/25881156
http://dx.doi.org/10.1186/s12885-015-1149-5
work_keys_str_mv AT weiqiong anticanceractivityofathymidinequinoxalineconjugateismodulatedbycytosolicthymidinepathways
AT liuhaijuan anticanceractivityofathymidinequinoxalineconjugateismodulatedbycytosolicthymidinepathways
AT zhouhonghao anticanceractivityofathymidinequinoxalineconjugateismodulatedbycytosolicthymidinepathways
AT zhangdejun anticanceractivityofathymidinequinoxalineconjugateismodulatedbycytosolicthymidinepathways
AT zhangzhiwei anticanceractivityofathymidinequinoxalineconjugateismodulatedbycytosolicthymidinepathways
AT zhouqibing anticanceractivityofathymidinequinoxalineconjugateismodulatedbycytosolicthymidinepathways